PMC:7335494 / 70141-70409 JSONTXT

Annnotations TAB JSON ListView MergeView

    LitCovid-PD-CLO

    {"project":"LitCovid-PD-CLO","denotations":[{"id":"T765","span":{"begin":29,"end":33},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_117565"},{"id":"T766","span":{"begin":80,"end":84},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_117565"}],"text":"4-month intervention:➢ 1.5 g fish oil (1042.5 mg EPA and 174 DHA daily)\n➢ 2.5 g fish oil (2085 mg EPA and 348 mg DHA daily)\n➢ placebo 138 ↓TNF-α and ↓ IL-6 for both low and high dose groups ↓ n-6:n-3 ratio for both low and high dose groups Kiecolt-Glaser et al. (2012)"}

    LitCovid-PD-CHEBI

    {"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T79332","span":{"begin":49,"end":52},"obj":"Chemical"},{"id":"T13298","span":{"begin":61,"end":64},"obj":"Chemical"},{"id":"T8354","span":{"begin":98,"end":101},"obj":"Chemical"},{"id":"T27856","span":{"begin":113,"end":116},"obj":"Chemical"},{"id":"T14050","span":{"begin":151,"end":153},"obj":"Chemical"}],"attributes":[{"id":"A77282","pred":"chebi_id","subj":"T79332","obj":"http://purl.obolibrary.org/obo/CHEBI_28364"},{"id":"A67313","pred":"chebi_id","subj":"T13298","obj":"http://purl.obolibrary.org/obo/CHEBI_16016"},{"id":"A73126","pred":"chebi_id","subj":"T13298","obj":"http://purl.obolibrary.org/obo/CHEBI_28125"},{"id":"A69606","pred":"chebi_id","subj":"T13298","obj":"http://purl.obolibrary.org/obo/CHEBI_28689"},{"id":"A65155","pred":"chebi_id","subj":"T13298","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"},{"id":"A7899","pred":"chebi_id","subj":"T8354","obj":"http://purl.obolibrary.org/obo/CHEBI_28364"},{"id":"A89962","pred":"chebi_id","subj":"T27856","obj":"http://purl.obolibrary.org/obo/CHEBI_16016"},{"id":"A68819","pred":"chebi_id","subj":"T27856","obj":"http://purl.obolibrary.org/obo/CHEBI_28125"},{"id":"A34305","pred":"chebi_id","subj":"T27856","obj":"http://purl.obolibrary.org/obo/CHEBI_28689"},{"id":"A44341","pred":"chebi_id","subj":"T27856","obj":"http://purl.obolibrary.org/obo/CHEBI_36005"},{"id":"A71332","pred":"chebi_id","subj":"T14050","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A17335","pred":"chebi_id","subj":"T14050","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"4-month intervention:➢ 1.5 g fish oil (1042.5 mg EPA and 174 DHA daily)\n➢ 2.5 g fish oil (2085 mg EPA and 348 mg DHA daily)\n➢ placebo 138 ↓TNF-α and ↓ IL-6 for both low and high dose groups ↓ n-6:n-3 ratio for both low and high dose groups Kiecolt-Glaser et al. (2012)"}

    LitCovid-sentences

    {"project":"LitCovid-sentences","denotations":[{"id":"T403","span":{"begin":0,"end":71},"obj":"Sentence"},{"id":"T404","span":{"begin":72,"end":123},"obj":"Sentence"},{"id":"T405","span":{"begin":124,"end":268},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"4-month intervention:➢ 1.5 g fish oil (1042.5 mg EPA and 174 DHA daily)\n➢ 2.5 g fish oil (2085 mg EPA and 348 mg DHA daily)\n➢ placebo 138 ↓TNF-α and ↓ IL-6 for both low and high dose groups ↓ n-6:n-3 ratio for both low and high dose groups Kiecolt-Glaser et al. (2012)"}

    MyTest

    {"project":"MyTest","denotations":[{"id":"32640331-22640930-30720989","span":{"begin":263,"end":267},"obj":"22640930"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"4-month intervention:➢ 1.5 g fish oil (1042.5 mg EPA and 174 DHA daily)\n➢ 2.5 g fish oil (2085 mg EPA and 348 mg DHA daily)\n➢ placebo 138 ↓TNF-α and ↓ IL-6 for both low and high dose groups ↓ n-6:n-3 ratio for both low and high dose groups Kiecolt-Glaser et al. (2012)"}

    2_test

    {"project":"2_test","denotations":[{"id":"32640331-22640930-30720989","span":{"begin":263,"end":267},"obj":"22640930"}],"text":"4-month intervention:➢ 1.5 g fish oil (1042.5 mg EPA and 174 DHA daily)\n➢ 2.5 g fish oil (2085 mg EPA and 348 mg DHA daily)\n➢ placebo 138 ↓TNF-α and ↓ IL-6 for both low and high dose groups ↓ n-6:n-3 ratio for both low and high dose groups Kiecolt-Glaser et al. (2012)"}